Irradiated riboflavin diminishes the aggressiveness of melanoma in vitro and in vivo.
Melanoma is one of the most aggressive skin cancers due to its high capacity to metastasize. Treatment of metastatic melanomas is challenging for clinicians, as most therapeutic agents have failed to demonstrate improved survival. Thus, new candidates with antimetastatic activity are much needed. Riboavin (RF) is a component of the vitamin B complex and a potent photosensitizer. Previously, our group showed that the RF photoproducts (iRF) have potential as an antitumoral agent. Hence, we investigated the capacity of iRF on modulating melanoma B16F10 cells aggressiveness in vitro and in vivo. iRF decreases B16F10 cells survival by inhibiting mTOR as well as Src kinase. Moreover, melanoma cell migration was disrupted after treatment with iRF, mainly by inhibition of metalloproteinase (MMP) activity and expression, and by increasing TIMP expression. Interestingly, we observed that the Hedgehog (HH) pathway was inhibited by iRF. Two mediators of HH signaling, GLI1 and PTCH, were downregulated, while SUFU expression (an inhibitor of this cascade) was enhanced. Furthermore, inhibition of HH pathway signaling by cyclopamine and Gant 61 potentiated the antiproliferative action of RF. Accordingly, when a HH ligand was applied, the effect of iRF was almost completely abrogated. Our findings indicate that Hedgehog pathway is involved on the modulation of melanoma cell aggressiveness by iRF. Moreover, iRF treatment decreased pulmonary tumor formation in a murine experimental metastasis model. Research to clarify the molecular action of flavins, in vivo, is currently in progress. Taken together, the present data provides evidence that riboflavin photoproducts may provide potential candidates for improving the efficiency of melanoma treatment.
Laboratory of Bioassays and Signal Transduction, Department of Biochemistry, Institute of Biology, University of Campinas, Campinas, São Paulo, Brazil.
Daisy
D
Machado
Silvia M
SM
Shishido
Karla C S
KC
Queiroz
Diogo N
DN
Oliveira
Ana L C
AL
Faria
Rodrigo R
RR
Catharino
C Arnold
CA
Spek
Carmen V
CV
Ferreira
D000818:Animals; D015153:Blotting, Western; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D005415:Flavins / Q000627:therapeutic use; D006801:Humans; D015603:Keratinocytes / Q000166:cytology / Q000187:drug effects; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D011725:Pyridines / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D012256:Riboflavin / Q000494:pharmacology* / Q000627:therapeutic use*; D014704:Veratrum Alkaloids / Q000494:pharmacology
D005415:Flavins; C551027:GANT 61; D011725:Pyridines; D011743:Pyrimidines; D014704:Veratrum Alkaloids; D012256:Riboflavin; C000541:cyclopamine